AB-101

Phase 2Small molecule

AArtiva Biotherapeutics, Inc.

AB-101 is one of 155 small molecule programs targeting Oral. It is currently in Phase 2.

Indications

Total Trials

Active Trials

154

Competitors

Pipeline

Status by Indication[3][1]

Indication

OralActive, not recruiting

Systemic Lupus ErythematosusActive, not recruiting

Autoimmune DiseaseRecruiting

LymphomaActive, not recruiting

OralPhase 1

Active, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Autoimmune DiseasePhase 1

Recruiting

LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

AB-101

AArtiva Biotherapeutics, Inc.

Phase 2

1 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 9

JY231

SShenzhen Genocury Biotech Co., Ltd.

Preclinical

1 10

R-CHOP

IIncyte Biosciences Japan GK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Systemic Lupus Erythematosus

NCT06265220

Q4 2028

Phase 1Recruiting

Autoimmune Disease

NCT06581562

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Study to Investigate the Effect of AB-101 in Breast Cancer Survivors

Completed·AApplied Biology, Inc.·Phase 1·NCT03592121·3 enrolled

Phase 21 trial

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

Terminated·AAffimed GmbH·Phase 2·NCT05883449·25 enrolled

Autoimmune Disease1 trial

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

Recruiting·IIRIS Research and Development, LLC·Phase 1·NCT06581562·30 enrolled

Systemic Lupus Erythematosus1 trial

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Active, not recruiting·AArtiva Biotherapeutics, Inc.·Phase 1·NCT06265220·51 enrolled

Oral1 trial

Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

Active, not recruiting·AArbutus Biopharma Corporation·Phase 1·NCT05960240·128 enrolled

1 more indication

Lymphoma1 trial

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Active, not recruiting·AArtiva Biotherapeutics, Inc.·Phase 1/2·NCT04673617·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for AB-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AB-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AB-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Artiva Biotherapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AArtiva Biotherapeutics, Inc.

AB-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Trials by Indication[1]

Breast Cancer1 trial

Phase 21 trial

Autoimmune Disease1 trial

Systemic Lupus Erythematosus1 trial

Oral1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News